索非那新

中文名称:

索非那新

中文同义词:

1-氮杂双环[2.2.2]辛烷-8-基-(1S)-1-苯基-3,4-二氢-1H-异喹啉-2-甲酸酯;索非那新;索利那新-D5;4R-羟基索利那新;4R-羟基SOLIFENACIN N-氧化物;(8R)-1-氮杂双环(2.2.2)辛烷-8-基-(1S)-1-苯基-3,4-二氢-1H-异喹啉-2-甲酸酯 (索非那新);(8R)-1-氮杂双环(2.2.2)辛烷-8-基-(1S)-1-苯基-3,4-二氢-1H-异喹啉-2-甲酸酯

英文名称:

Solifenacin

英文同义词:

Unii-A8910sqj1u;3,4-dihydro-1-phenyl-(1S)-2(1H)-Isoquinolinecarboxylic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester;YM 905;(1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate;2(1H)-Isoquinolinecarboxylicacid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)-;Solif·Nacin;4R-Hydroxy Solifenacin;4R-Hydroxy Solifenacin N-Oxide

CAS号:

242478-37-1

分子式:

C23H26N2O2

分子量:

362.46

EINECS号:

相关类别:

医药中间体;肠胃泌尿生殖系统类;医药原料;VESICARE

Mol文件:

242478-37-1.mol

沸点 

505.5±50.0 °C(Predicted)

密度 

1.24±0.1 g/cm3(Predicted)

酸度系数(pKa)

9.03±0.33(Predicted)

生物活性

Solifenacin (YM905 free base) 是一种新型的毒蕈碱受体 (muscarinic receptor) 拮抗剂，对 M1，M2 和 M3 受体的 pKi 值分别为 7.6, 6.9 和 8.0。

靶点

pKi: 7.6 (M 1 receptor), 6.9 (M 2 receptor), 8.0 (M 3 receptor)

体外研究

Solifenacin is a novel muscarinic receptor antagonist with pK i s of 7.6±0.056, 6.9±0.034 and 8.0±0.021 for M1, M2 and M3 receptors, respectively. In murine submandibular gland cells, the antagonistic effects of 100 nM Solifenacin and oxybutynin on Ca 2+ mobilization evoked by varying doses of carbachol (CCh) are examined. Solifenacin does not shift the CCh dose-activation curve in a parallel manner whereas oxybutynin shows insurmountable antagonism. The pK b values are obtained as 7.4±0.17 for Solifenacin and 8.8±0.21 for oxybutynin.

体内研究

Solifenacin reduces bladder responses by 40% at a dose of 210 nmol/kg (0.1 mg/kg) and abolishes them at 2100 nmol/kg (1 mg/kg). In contrast, its inhibitory effects on salivary and cardiac responses are only slight at 630 nmol/kg (0.3 mg/kg), and reach 66% and 49%, respectively, at 2100 nmol/kg (1 mg/kg). At doses of 63 and 210 nmol/kg (0.03 and 0.1 mg/kg), Solifenacin slightly increases saliva secretion. Solifenacin (0.01 to 0.3 mg/kg i.v.) dose-dependently increases bladder capacity and voided volume at doses of 0.03 mg/kg i.v. or more, but does not affect residual volume or micturition pressure at any dose tested.